Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol. In press.

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F, Aine M, Bernard-Pierrot I, Czerniak B, Gibb EA, Kim J, Kwiatkowski DJ, Lebret T, Liedberg F, Siefker-Radtke AA, Sirab N, Taber A, Weinstein JN.

Eur Urol. 2020 Feb 6. pii: S0302-2838(19)30958-3. doi: 10.1016/j.eururo.2019.12.014. [Epub ahead of print] No abstract available.

PMID:
32037144
2.

Re: Aurélie Kamoun, Aurélien de Reyniès, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.09.006: A Statement from the International Bladder Cancer Network.

Williams SB, Black PC, Dyrskjøt L, Seiler R, Schmitz-Dräger B, Nawroth R, Todenhöfer T, Kamat AM, Goebell PJ.

Eur Urol. 2019 Nov 28. pii: S0302-2838(19)30874-7. doi: 10.1016/j.eururo.2019.11.011. [Epub ahead of print] No abstract available.

PMID:
31787429
3.

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F; Bladder Cancer Molecular Taxonomy Group.

Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30695-5. doi: 10.1016/j.eururo.2019.09.006. [Epub ahead of print]

4.

Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend's Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as, a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019, 76:9-13.

Shi MJ, Meng XY, Chen CL, Dyrskjøt L, Radvanyi F, Prokunina-Olsson L, Bernard-Pierrot I.

Eur Urol. 2020 Jan;77(1):e26-e27. doi: 10.1016/j.eururo.2019.08.012. Epub 2019 Sep 5. No abstract available.

PMID:
31493961
5.

Autophagy role(s) in response to oncogenes and DNA replication stress.

Vanzo R, Bartkova J, Merchut-Maya JM, Hall A, Bouchal J, Dyrskjøt L, Frankel LB, Gorgoulis V, Maya-Mendoza A, Jäättelä M, Bartek J.

Cell Death Differ. 2019 Aug 14. doi: 10.1038/s41418-019-0403-9. [Epub ahead of print]

PMID:
31409894
6.

Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.

Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu HT, Tin AS, Heilskov Rasmussen M, Vang S, Shchegrova S, Frydendahl Boll Johansen A, Srinivasan R, Assaf Z, Balcioglu M, Olson A, Dashner S, Hafez D, Navarro S, Goel S, Rabinowitz M, Billings P, Sigurjonsson S, Dyrskjøt L, Swenerton R, Aleshin A, Laurberg S, Husted Madsen A, Kannerup AS, Stribolt K, Palmelund Krag S, Iversen LH, Gotschalck Sunesen K, Lin CJ, Zimmermann BG, Lindbjerg Andersen C.

JAMA Oncol. 2019 May 9. doi: 10.1001/jamaoncol.2019.0528. [Epub ahead of print] Erratum in: JAMA Oncol. 2019 Jun 13;:.

7.

Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.

Christensen E, Birkenkamp-Demtröder K, Sethi H, Shchegrova S, Salari R, Nordentoft I, Wu HT, Knudsen M, Lamy P, Lindskrog SV, Taber A, Balcioglu M, Vang S, Assaf Z, Sharma S, Tin AS, Srinivasan R, Hafez D, Reinert T, Navarro S, Olson A, Ram R, Dashner S, Rabinowitz M, Billings P, Sigurjonsson S, Andersen CL, Swenerton R, Aleshin A, Zimmermann B, Agerbæk M, Lin CJ, Jensen JB, Dyrskjøt L.

J Clin Oncol. 2019 Jun 20;37(18):1547-1557. doi: 10.1200/JCO.18.02052. Epub 2019 May 6.

PMID:
31059311
8.

Identification of ADAM12 as a Novel Basigin Sheddase.

Albrechtsen R, Wewer Albrechtsen NJ, Gnosa S, Schwarz J, Dyrskjøt L, Kveiborg M.

Int J Mol Sci. 2019 Apr 22;20(8). pii: E1957. doi: 10.3390/ijms20081957.

9.

APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.

Shi MJ, Meng XY, Lamy P, Banday AR, Yang J, Moreno-Vega A, Chen CL, Dyrskjøt L, Bernard-Pierrot I, Prokunina-Olsson L, Radvanyi F.

Eur Urol. 2019 Jul;76(1):9-13. doi: 10.1016/j.eururo.2019.03.032. Epub 2019 Apr 8.

PMID:
30975452
10.

Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts.

Sikic D, Wirtz RM, Wach S, Dyrskjøt L, Erben P, Bolenz C, Breyer J, Otto W, Hoadley KA, Lerner SP, Eckstein M, Hartmann A, Keck B.

Transl Oncol. 2019 Apr;12(4):661-668. doi: 10.1016/j.tranon.2019.01.005. Epub 2019 Mar 2.

11.

Large-scale genomic comparison of UTUC and bladder tumours.

Dyrskjøt L.

Nat Rev Urol. 2019 Mar;16(3):149-150. doi: 10.1038/s41585-019-0145-y. No abstract available.

PMID:
30647442
12.

Molecular Subtypes of Bladder Cancer: Academic Exercise or Clinical Relevance?

Dyrskjøt L.

Eur Urol. 2019 Mar;75(3):433-434. doi: 10.1016/j.eururo.2018.09.006. Epub 2018 Sep 17. No abstract available.

PMID:
30237022
13.

Biology of nonmuscle-invasive bladder cancer: pathology, genomic implications, and immunology.

Dyrskjøt L, Ingersoll MA.

Curr Opin Urol. 2018 Nov;28(6):598-603. doi: 10.1097/MOU.0000000000000543. Review.

PMID:
30138123
14.

Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases.

Sjödahl G, Eriksson P, Lövgren K, Marzouka NA, Bernardo C, Nordentoft I, Dyrskjøt L, Liedberg F, Höglund M.

Mod Pathol. 2018 Dec;31(12):1869-1881. doi: 10.1038/s41379-018-0096-5. Epub 2018 Jul 2.

15.

FOXM1 predicts disease progression in non-muscle invasive bladder cancer.

Rinaldetti S, Wirtz R, Worst TS, Hartmann A, Breyer J, Dyrskjot L, Erben P.

J Cancer Res Clin Oncol. 2018 Sep;144(9):1701-1709. doi: 10.1007/s00432-018-2694-5. Epub 2018 Jun 29.

16.

STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer.

Lelo A, Prip F, Harris BT, Solomon D, Berry DL, Chaldekas K, Kumar A, Simko J, Jensen JB, Bhattacharyya P, Mannion C, Kim JS, Philips G, Dyrskjøt L, Waldman T.

Clin Cancer Res. 2018 Sep 1;24(17):4145-4153. doi: 10.1158/1078-0432.CCR-17-3244. Epub 2018 Jun 28.

17.

Optimized targeted sequencing of cell-free plasma DNA from bladder cancer patients.

Christensen E, Nordentoft I, Vang S, Birkenkamp-Demtröder K, Jensen JB, Agerbæk M, Pedersen JS, Dyrskjøt L.

Sci Rep. 2018 Jan 30;8(1):1917. doi: 10.1038/s41598-018-20282-8.

18.

Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups.

van Kessel KEM, van der Keur KA, Dyrskjøt L, Algaba F, Welvaart NYC, Beukers W, Segersten U, Keck B, Maurer T, Simic T, Horstmann M, Grimm MO, Hermann GG, Mogensen K, Hartmann A, Harving N, Petersen AC, Jensen JB, Junker K, Boormans JL, Real FX, Malats N, Malmström PU, Ørntoft TF, Zwarthoff EC.

Clin Cancer Res. 2018 Apr 1;24(7):1586-1593. doi: 10.1158/1078-0432.CCR-17-2719. Epub 2018 Jan 24.

19.

Circular RNA expression is abundant and correlated to aggressiveness in early-stage bladder cancer.

Okholm TLH, Nielsen MM, Hamilton MP, Christensen LL, Vang S, Hedegaard J, Hansen TB, Kjems J, Dyrskjøt L, Pedersen JS.

NPJ Genom Med. 2017 Nov 28;2:36. doi: 10.1038/s41525-017-0038-z. eCollection 2017.

20.

Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients.

Chan OTM, Furuya H, Pagano I, Shimizu Y, Hokutan K, Dyrskjøt L, Jensen JB, Malmstrom PU, Segersten U, Janku F, Rosser CJ.

Oncotarget. 2017 Sep 6;8(59):99707-99721. doi: 10.18632/oncotarget.20686. eCollection 2017 Nov 21.

21.

Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis.

Birkenkamp-Demtröder K, Christensen E, Nordentoft I, Knudsen M, Taber A, Høyer S, Lamy P, Agerbæk M, Jensen JB, Dyrskjøt L.

Eur Urol. 2018 Apr;73(4):535-540. doi: 10.1016/j.eururo.2017.09.011. Epub 2017 Sep 27.

PMID:
28958829
22.

Exosomes of invasive urothelial carcinoma cells are characterized by a specific miRNA expression signature.

Baumgart S, Hölters S, Ohlmann CH, Bohle R, Stöckle M, Ostenfeld MS, Dyrskjøt L, Junker K, Heinzelmann J.

Oncotarget. 2017 May 4;8(35):58278-58291. doi: 10.18632/oncotarget.17619. eCollection 2017 Aug 29.

23.

Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer.

Thomsen MBH, Nordentoft I, Lamy P, Vang S, Reinert L, Mapendano CK, Høyer S, Ørntoft TF, Jensen JB, Dyrskjøt L.

Sci Rep. 2017 Sep 15;7(1):11702. doi: 10.1038/s41598-017-11291-0.

24.

Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.

Dyrskjøt L, Reinert T, Algaba F, Christensen E, Nieboer D, Hermann GG, Mogensen K, Beukers W, Marquez M, Segersten U, Høyer S, Ulhøi BP, Hartmann A, Stöhr R, Wach S, Nawroth R, Schwamborn K, Tulic C, Simic T, Junker K, Harving N, Petersen AC, Jensen JB, Keck B, Grimm MO, Horstmann M, Maurer T, Steyerberg EW, Zwarthoff EC, Real FX, Malats N, Malmström PU, Ørntoft TF.

Eur Urol. 2017 Sep;72(3):461-469. doi: 10.1016/j.eururo.2017.05.040. Epub 2017 Jun 2.

PMID:
28583312
25.

Toward personalized management in bladder cancer: the promise of novel molecular taxonomy.

Eich ML, Dyrskjøt L, Netto GJ.

Virchows Arch. 2017 Aug;471(2):271-280. doi: 10.1007/s00428-017-2119-x. Epub 2017 Apr 21. Review.

PMID:
28429075
26.

Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.

Choi W, Ochoa A, McConkey DJ, Aine M, Höglund M, Kim WY, Real FX, Kiltie AE, Milsom I, Dyrskjøt L, Lerner SP.

Eur Urol. 2017 Sep;72(3):354-365. doi: 10.1016/j.eururo.2017.03.010. Epub 2017 Mar 30. Review.

27.

Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer.

Seitz AK, Christensen LL, Christensen E, Faarkrog K, Ostenfeld MS, Hedegaard J, Nordentoft I, Nielsen MM, Palmfeldt J, Thomson M, Jensen MT, Nawroth R, Maurer T, Ørntoft TF, Jensen JB, Damgaard CK, Dyrskjøt L.

Sci Rep. 2017 Mar 24;7(1):395. doi: 10.1038/s41598-017-00327-0.

28.

Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.

Christensen E, Birkenkamp-Demtröder K, Nordentoft I, Høyer S, van der Keur K, van Kessel K, Zwarthoff E, Agerbæk M, Ørntoft TF, Jensen JB, Dyrskjøt L.

Eur Urol. 2017 Jun;71(6):961-969. doi: 10.1016/j.eururo.2016.12.016. Epub 2017 Jan 6.

PMID:
28069289
29.

FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.

Beukers W, van der Keur KA, Kandimalla R, Vergouwe Y, Steyerberg EW, Boormans JL, Jensen JB, Lorente JA, Real FX, Segersten U, Orntoft TF, Malats N, Malmström PU, Dyrskjot L, Zwarthoff EC.

J Urol. 2017 Jun;197(6):1410-1418. doi: 10.1016/j.juro.2016.12.096. Epub 2016 Dec 31.

PMID:
28049011
30.

Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review?

Solomon JP, Lowenthal BM, Kader AK, Parsons JK, Flaig TW, Siefker-Radtke AO, Dyrskjøt L, Hansel DE.

Urology. 2017 Apr;102:7-16. doi: 10.1016/j.urology.2016.10.014. Epub 2016 Oct 18. Review.

PMID:
27769917
31.

Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.

van Kessel KE, Beukers W, Lurkin I, Ziel-van der Made A, van der Keur KA, Boormans JL, Dyrskjøt L, Márquez M, Ørntoft TF, Real FX, Segersten U, Malats N, Malmström PU, Van Criekinge W, Zwarthoff EC.

J Urol. 2017 Mar;197(3 Pt 1):590-595. doi: 10.1016/j.juro.2016.09.118. Epub 2016 Oct 13.

PMID:
27746284
32.

Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma.

Thomsen MB, Nordentoft I, Lamy P, Høyer S, Vang S, Hedegaard J, Borre M, Jensen JB, Ørntoft TF, Dyrskjøt L.

Mol Oncol. 2016 Nov;10(9):1450-1460. doi: 10.1016/j.molonc.2016.08.003. Epub 2016 Aug 17.

33.

Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma.

Lamy P, Nordentoft I, Birkenkamp-Demtröder K, Thomsen MB, Villesen P, Vang S, Hedegaard J, Borre M, Jensen JB, Høyer S, Pedersen JS, Ørntoft TF, Dyrskjøt L.

Cancer Res. 2016 Oct 1;76(19):5894-5906. Epub 2016 Aug 3.

34.

Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.

Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MBH, Nielsen MM, Marquez M, Segersten U, Aine M, Höglund M, Birkenkamp-Demtröder K, Fristrup N, Borre M, Hartmann A, Stöhr R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KEM, Jensen JB, Pedersen JS, Malmström PU, Malats N, Real FX, Zwarthoff EC, Ørntoft TF, Dyrskjøt L.

Cancer Cell. 2016 Jul 11;30(1):27-42. doi: 10.1016/j.ccell.2016.05.004. Epub 2016 Jun 16.

35.

The Splicing Efficiency of Activating HRAS Mutations Can Determine Costello Syndrome Phenotype and Frequency in Cancer.

Hartung AM, Swensen J, Uriz IE, Lapin M, Kristjansdottir K, Petersen US, Bang JM, Guerra B, Andersen HS, Dobrowolski SF, Carey JC, Yu P, Vaughn C, Calhoun A, Larsen MR, Dyrskjøt L, Stevenson DA, Andresen BS.

PLoS Genet. 2016 May 19;12(5):e1006039. doi: 10.1371/journal.pgen.1006039. eCollection 2016 May.

36.

Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.

Kristensen H, Thomsen AR, Haldrup C, Dyrskjøt L, Høyer S, Borre M, Mouritzen P, Ørntoft TF, Sørensen KD.

Oncotarget. 2016 May 24;7(21):30760-71. doi: 10.18632/oncotarget.8953.

37.

Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.

Birkenkamp-Demtröder K, Nordentoft I, Christensen E, Høyer S, Reinert T, Vang S, Borre M, Agerbæk M, Jensen JB, Ørntoft TF, Dyrskjøt L.

Eur Urol. 2016 Jul;70(1):75-82. doi: 10.1016/j.eururo.2016.01.007. Epub 2016 Jan 20.

PMID:
26803478
38.

Tumour exosomes display differential mechanical and complement activation properties dependent on malignant state: implications in endothelial leakiness.

Whitehead B, Wu L, Hvam ML, Aslan H, Dong M, Dyrskjøt L, Ostenfeld MS, Moghimi SM, Howard KA.

J Extracell Vesicles. 2015 Dec 28;4:29685. doi: 10.3402/jev.v4.29685. eCollection 2015.

39.

Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy.

Mortensen MM, Høyer S, Lynnerup AS, Ørntoft TF, Sørensen KD, Borre M, Dyrskjøt L.

Sci Rep. 2015 Nov 2;5:16018. doi: 10.1038/srep16018.

40.

High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy.

Mortensen MM, Høyer S, Orntoft TF, Sørensen KD, Dyrskjøt L, Borre M.

BMC Cancer. 2014 Nov 21;14:859. doi: 10.1186/1471-2407-14-859.

41.

Comparative analysis of discrete exosome fractions obtained by differential centrifugation.

Jeppesen DK, Hvam ML, Primdahl-Bengtson B, Boysen AT, Whitehead B, Dyrskjøt L, Orntoft TF, Howard KA, Ostenfeld MS.

J Extracell Vesicles. 2014 Nov 6;3:25011. doi: 10.3402/jev.v3.25011. eCollection 2014.

42.

Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties.

Ostenfeld MS, Jeppesen DK, Laurberg JR, Boysen AT, Bramsen JB, Primdal-Bengtson B, Hendrix A, Lamy P, Dagnaes-Hansen F, Rasmussen MH, Bui KH, Fristrup N, Christensen EI, Nordentoft I, Morth JP, Jensen JB, Pedersen JS, Beck M, Theodorescu D, Borre M, Howard KA, Dyrskjøt L, Ørntoft TF.

Cancer Res. 2014 Oct 15;74(20):5758-71. doi: 10.1158/0008-5472.CAN-13-3512. Epub 2014 Sep 26.

43.

High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer.

Laurberg JR, Jensen JB, Schepeler T, Borre M, Ørntoft TF, Dyrskjøt L.

BMC Cancer. 2014 Aug 30;14:638. doi: 10.1186/1471-2407-14-638.

44.

External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort.

Chen LM, Chang M, Dai Y, Chai KX, Dyrskjøt L, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Lokeshwar V, Jeronimo C, Parker AS, Ross S, Borre M, Orntoft TF, Jaeger T, Beukers W, Lopez LE, Henrique R, Young PR, Urquidi V, Goodison S, Rosser CJ.

Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1804-12. doi: 10.1158/1055-9965.EPI-14-0029. Epub 2014 Jun 11.

45.

Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours.

Vedder MM, Márquez M, de Bekker-Grob EW, Calle ML, Dyrskjøt L, Kogevinas M, Segersten U, Malmström PU, Algaba F, Beukers W, Ørntoft TF, Zwarthoff E, Real FX, Malats N, Steyerberg EW.

PLoS One. 2014 Jun 6;9(6):e96849. doi: 10.1371/journal.pone.0096849. eCollection 2014.

46.

Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue.

Hedegaard J, Thorsen K, Lund MK, Hein AM, Hamilton-Dutoit SJ, Vang S, Nordentoft I, Birkenkamp-Demtröder K, Kruhøffer M, Hager H, Knudsen B, Andersen CL, Sørensen KD, Pedersen JS, Ørntoft TF, Dyrskjøt L.

PLoS One. 2014 May 30;9(5):e98187. doi: 10.1371/journal.pone.0098187. eCollection 2014.

47.

Mutational context and diverse clonal development in early and late bladder cancer.

Nordentoft I, Lamy P, Birkenkamp-Demtröder K, Shumansky K, Vang S, Hornshøj H, Juul M, Villesen P, Hedegaard J, Roth A, Thorsen K, Høyer S, Borre M, Reinert T, Fristrup N, Dyrskjøt L, Shah S, Pedersen JS, Ørntoft TF.

Cell Rep. 2014 Jun 12;7(5):1649-1663. doi: 10.1016/j.celrep.2014.04.038. Epub 2014 May 15.

48.

Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer.

Teo MT, Dyrskjøt L, Nsengimana J, Buchwald C, Snowden H, Morgan J, Jensen JB, Knowles MA, Taylor G, Barrett JH, Borre M, Orntoft TF, Bishop DT, Kiltie AE.

Ann Oncol. 2014 Apr;25(4):877-83. doi: 10.1093/annonc/mdu014. Epub 2014 Mar 12.

49.

Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors.

Jeppesen DK, Nawrocki A, Jensen SG, Thorsen K, Whitehead B, Howard KA, Dyrskjøt L, Ørntoft TF, Larsen MR, Ostenfeld MS.

Proteomics. 2014 Mar;14(6):699-712. doi: 10.1002/pmic.201300452. Epub 2014 Feb 16. Erratum in: Proteomics. 2014 Nov;14(21-22):2628-9.

PMID:
24376083
50.

The use of molecular analyses in voided urine for the assessment of patients with hematuria.

Beukers W, Kandimalla R, van Houwelingen D, Kovacic H, Chin JF, Lingsma HF, Dyrskjot L, Zwarthoff EC.

PLoS One. 2013 Oct 15;8(10):e77657. doi: 10.1371/journal.pone.0077657. eCollection 2013.

Supplemental Content

Loading ...
Support Center